Immix Biopharma (IMMX) Price & Analysis

Compare

184 Followers

IMMX Stock Chart & Stats

$4.32

-$0.03(-1.32%)

At close: Jan 08 4:00 PM EST

$4.32

-$0.03(-1.32%)

Day’s Range― - ―

52-Week Range$1.34 - $7.45

Previous Close$2.25

Volume74.23K

Average Volume (3M)683.60K

Market Cap

$186.69M

Enterprise ValueN/A

Total Cash (Recent Filing)$15.95M

Total Debt (Recent Filing)$1.11M

Price to Earnings (P/E)―

Beta1.75

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding33,577,873

10 Day Avg. Volume476,730

30 Day Avg. Volume683,602

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)4.70

Price to Sales (P/S)0.00

P/FCF Ratio-3.95

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$8.00

Price Target Upside85.19% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.71

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessNXC-201 demonstrated a 75% hematologic complete response rate in the NEXICART-2 trial for r/r AL amyloidosis.

Market OpportunityThere are currently no FDA-approved agents available for treatment of r/r AL amyloidosis, indicating a potential market opportunity for Immix's treatment.

Regulatory Approval OutlookAnalyst increased the probability of approval for NXC-201 in r/r AL amyloidosis to 85%, up from the prior 40%.

Bears Say

Competitive ThreatEtentamig poses a potential competitive threat to NXC-201 in the treatment of r/r AL amyloidosis.

Financial PerformanceImmix reported a higher-than-expected net loss for 3Q25, with increased R&D and SG&A expenses contributing to this outcome.

Immix Biopharma News

Immix Biopharma price target raised to $12 from $8 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $12 from $8 and keeps a...

3d ago

IMMX

Immix Biopharma 19.12M share Spot Secondary priced at $5.10

Morgan Stanley acted as lead book running manager for the offering. Published first on TheFly – the ultimate...

4d ago

IMMX

Immix Biopharma announces phase 2 NXC-201 results

Immix Biopharma (IMMX) announced positive phase 2 NXC-201 results in an oral presentation at ASH 2025 presented by...

5d ago

IMMX

Immix Biopharma Enters Underwriting Agreement with Morgan Stanley

The latest announcement is out from Immix Biopharma ( ($IMMX) ). On December 7, 2025, Immix Biopharma, Inc....

4d ago

IMMX

Immix Biopharma Announces Positive Phase 2 Trial Results

The latest announcement is out from Immix Biopharma ( ($IMMX) ). On December 7, 2025, Immix Biopharma announced...

4d ago

IMMX

Immix Biopharma Updates Accounting Firm Consents

The latest announcement is out from Immix Biopharma ( ($IMMX) ). Immix Biopharma, Inc. has updated its consents...

16d ago

IMMX

Immix Biopharma appoints Grabow as Chief Commercial Officer

Immix Biopharma (IMMX) announced the appointment of former Chimerix senior commercial leader Michael Grabow as Chief Commercial Officer....

1M ago

IMMX

Immix Biopharma: Promising Trial Results and Strong Financial Position Justify Buy Rating

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Immix Biopharma and increased the price target...

1M ago

IMMX

Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis

Immix Biopharma, Inc. (($IMMX)) announced an update on their ongoing clinical study. Immix Biopharma, Inc. is collaborating on...

2M ago

IMMX

Immix Biopharma files to sell 6.85M shares of common stock for holders

08:11 EDT Immix Biopharma (IMMX) files to sell 6.85M shares of common stock for holders Published first on...

2M ago

IMMX

Immix Biopharma price target raised to $8 from $7 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $8 from $7 and keeps a...

3M ago

IMMX

Immix Biopharma appoints Nancy Chang to board of directors

Immix Biopharma (IMMX) announced that Nancy Chang, former Tanox CEO, has joined the Immix Biopharma Board of Directors...

3M ago

IMMX

Immix Biopharma Completes Private Placement Transaction

The latest announcement is out from Immix Biopharma ( ($IMMX) ). On September 5, 2025, Immix Biopharma, Inc....

3M ago

IMMX

Immix Biopharma receives strategic investment from Goose Capital

Immix Biopharma (IMMX) announced that it has received a strategic investment from Goose Capital and former Tanox, Inc....

3M ago

IMMX

IMMX FAQ

What was Immix Biopharma, Inc.’s price range in the past 12 months?

Immix Biopharma, Inc. lowest stock price was $1.34 and its highest was $7.45 in the past 12 months.

What is Immix Biopharma, Inc.’s market cap?

Immix Biopharma, Inc.’s market cap is $186.69M.

When is Immix Biopharma, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Immix Biopharma, Inc.’s earnings last quarter?

Currently, no data Available

Is Immix Biopharma, Inc. overvalued?

According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immix Biopharma, Inc. pay dividends?

Immix Biopharma, Inc. does not currently pay dividends.

What is Immix Biopharma, Inc.’s EPS estimate?

Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immix Biopharma, Inc. have?

Immix Biopharma, Inc. has 33,577,873 shares outstanding.

What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Immix Biopharma, Inc.?

Currently, no hedge funds are holding shares in IMMX

Immix Biopharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-182.55%

Trailing 12-Months

Asset Growth

-20.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

IMMX Stock 12 Month Forecast

Average Price Target

$8.00

▲(85.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Jan<br/>2025","9":"Jul<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.03,4.335384615384616,4.640769230769231,4.946153846153846,5.251538461538462,5.556923076923077,5.862307692307692,6.167692307692308,6.473076923076923,6.7784615384615385,7.083846153846154,7.389230769230769,7.694615384615385,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.03,4.335384615384616,4.640769230769231,4.946153846153846,5.251538461538462,5.556923076923077,5.862307692307692,6.167692307692308,6.473076923076923,6.7784615384615385,7.083846153846154,7.389230769230769,7.694615384615385,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.03,4.335384615384616,4.640769230769231,4.946153846153846,5.251538461538462,5.556923076923077,5.862307692307692,6.167692307692308,6.473076923076923,6.7784615384615385,7.083846153846154,7.389230769230769,7.694615384615385,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.36,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >